Image ADN pour la caractérisation des cancers

Characterizing cancers
to understand them better

The Genexpath company develops and markets
innovative tests based on Next Generation Sequencing
to better characterize cancers

From research to medical applications

Genexpath is designing and marketing next-generation diagnostic tests to better characterize cancers such as non-Hodgkin's lymphomas and sarcomas. Better characterizing cancers means better understanding and therefore better treatment.

Genexpath was born from the desire of a researchers team to see their research benefit to the greatest number and to allow practitioners to be able to refine their analyzes effectively.
This research work is therefore now accessible to pathologists and molecular biologists all over the world.

A team of specialists and key partners

The Genexpath team is at your service on a daily basis to offer you quality products.

From design to production, from quality control to marketing, it works on the innovative solutions of tomorrow adapted to your needs in order to save you time.

Our products

Exchange and share

Genexpath participates at national and international pathology congresses to discuss with professionals, users and work on tomorrow's products . Partners, interlocutors or users, come and meet us on our booths.

Genexpath à la SFMPP

Genexpath was at SFMPP 8th congress for the session "French start-ups and innovation in genomic medicine" on October 6, 2022

See video

Contact us

If you need to ask us a question or find out more about the company and its products, contact us. We will be delighted to meet you at international congresses, do not hesitate to visit us